Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature

Samantha E. Jacobs, Deborah Saez-Lacy, Walter Wynkoop, and Thomas J. Walsh

Isavuconazole is a new triazole that is approved for primary therapy of invasive aspergillosis. We provide the first report of a patient with allergic bronchopulmonary aspergillosis (ABPA) who was successfully treated with isavuconazole with marked improvement and minimal adverse effects. We further review the literature on antifungal management of ABPA.

Keywords. allergic bronchopulmonary aspergillosis; antifungal therapy; isavuconazole.

Allergic bronchopulmonary aspergillosis (ABPA) results from an abnormal exaggerated local and systemic immune response to conidia and hyphae colonizing the sinopulmonary tract. Allergic bronchopulmonary aspergillosis complicates asthma and cystic fibrosis in 1%–2% and 5%–15% of patients, respectively [1]. In asthmatic patients, ABPA presents as poorly controlled asthma with wheezing, cough, sputum production, low-grade fever, weight loss, and malaise.

Allergic bronchopulmonary aspergillosis management includes corticosteroids to control the host immune response and antifungal agents to decrease the burden of organism. Itraconazole is currently the first-line agent for symptomatic ABPA patients based on randomized, controlled clinical trials [2, 3]. Voriconazole is an alternative based on observational data [4]. However, both itraconazole and voriconazole are associated with significant adverse effects.

Isavuconazole is a broad-spectrum antifungal triazole with potent activity against *Aspergillus* species. It is recommended as an alternative primary therapy for invasive aspergillosis syndromes in the 2016 Infectious Diseases Society of America Guidelines [5]. We provide the first report of a patient with ABPA who was successfully treated with isavuconazole after having persistent symptoms and significant side effects with itraconazole and voriconazole.

METHODS

We first sought to understand the impact of systemic antifungal management on ABPA. We therefore systematically searched the PubMed database for English-language literature of antifungal therapy for ABPA in patients with underlying asthma. The following search terms were used: “itraconazole,” “voriconazole,” “posaconazole,” “isavuconazole,” “nebulized amphotericin B,” and “allergic bronchopulmonary aspergillosis.” We then report in detail our index case.

CASE REPORT

A 56-year-old female physician with asthma was seen in consultation in May 2015 for ABPA management. Her symptoms began in September 2009 when she developed a flu-like illness with fever, malaise, nonproductive cough, and decreased exercise tolerance. She regularly attended aerobic exercise classes, but she found that any activity that increased her respiratory rate lead to coughing “fits” that precluded further exercise.

In the spring of 2010, the cough and wheezing worsened, and she had new sputum production. A serum immunoglobulin (Ig)E level was 813 IU/mL, precipitating serum IgG antibodies to *Aspergillus fumigatus* were detected, *Aspergillus* skin testing was positive, and a sputum culture grew *A. fumigatus*. A high-resolution computed tomography (CT) scan of the chest demonstrated mild hyperinflation of the lungs bilaterally and minimal inflammatory changes in the left mid-lung field. Pulmonary function tests (PFTs) revealed obstructive airways disease (forced expiratory volume [FEV], 2.08L, forced vital capacity [FVC] 3.02L, FEV/FVC 69%) that did not improve after bronchodilator therapy. The patient was diagnosed with ABPA. In October 2010, she was prescribed prednisone 0.5 mg/kg orally daily for 1 week followed by a taper over 3 months. Her respiratory symptoms improved such that she could participate in aerobic gym classes. The serum IgE decreased to 326 IU/mL. However, she was unable to discontinue corticosteroids entirely. Sputum cultures continued to grow *Aspergillus* species through July 2011. Pulmonary function tests showed stable mild obstruction.

Over the next year, her chronic cough and sputum production continued, and she lost 15 pounds unintentionally. She resumed prednisone at approximately 1 mg/kg in October 2011.
In December 2011, she started itraconazole; however, she developed hives, and the drug was discontinued. She was then treated with voriconazole 200 mg orally twice daily, and the cough and sputum production improved significantly. Prednisone was then tapered and discontinued. The serum IgE decreased from 663 IU/mL to 384 IU/mL. In March 2012, she stopped voriconazole due to an asymptomatic rise in the serum alanine aminotransferase (ALT) to 247 IU/L.

In fall 2012 and winter 2013, she had recurrent bronchitis and pneumonia due to *Pseudomonas aeruginosa*. A high-resolution CT scan of the chest showed cylindrical bronchiectasis in both lower lobes and bilateral, multiple, tiny lung nodules. Within the left lower lobe posterior basal segment, a $5.1 \times 4.5 \times 2.0$ cm opacity was seen. Thick, white sputum was noted throughout the airways during bronchoscopy. Culture of bronchoalveolar lavage fluid grew *Aspergillus* species, *Cladosporium* species, and *Stenotrophomonas maltophilia*. Antifungal susceptibility data were not available. The patient resumed voriconazole in September 2014 and again had marked clinical improvement. The IgE levels decreased from 1583 IU/mL to 787 IU/mL. Pulmonary function tests showed moderate obstruction (FEV$_1$, 1.61L, FEV$_1$/FVC 68%). However, she experienced photopsia, and serum ALT increased to more than twice the upper limit of normal. Voriconazole was discontinued in March 2015. Given that the patient was not able to tolerate voriconazole and was concerned about the adverse effects of corticosteroids, she presented to New York-Presbyterian Hospital/Weill Cornell Medicine for further management.

Additional past medical history included corticosteroid-induced diabetes (diet-controlled), osteopenia, and seasonal allergies. Medications included *N*-acetylcysteine nebulizers, albuterol sulfate inhaler, azelastine-fluticasone nasal spray, beclomethasone inhaler, budesonide-formoterol inhaler, fexofenadine, and montelukast.

On physical examination, vital signs were unremarkable. The oxygen saturation was 96% while breathing ambient air. The body mass index was 17.4 kg/m$^2$. Mid-inspiratory and expiratory wheezing was auscultated throughout the lung fields. The remainder of the exam was normal. Serum IgE level was 676 IU/mL. Erythrocyte sedimentation rate was 20 mm/hour (normal 0–40 mm/hour) and C-reactive protein was 0.5 mg/L (normal 0.0–4.9 mg/L).

Given the patient’s poor tolerance of corticosteroids (osteopenia and hyperglycemia), voriconazole (photopsia and elevated aspartate aminotransferase [AST] and ALT), and itraconazole (hypersensitivity reaction), she was prescribed oral isavuconazole 200 mg every 8 hours × 2 days, followed by 200 mg once daily. She was instructed to take isavuconazole in 4-month “pulses” so as to alleviate symptoms during ABPA exacerbations while reducing the risk of emergence of resistance. Over several weeks, she noted marked improvement in her sputum production and wheezing, and she was even able to backpack 16 miles in July 2015. She discontinued beclomethasone and continued on budesonide-formoterol alone. The serum IgE level remained elevated at 732 IU/mL. In August 2015, after 10 weeks of therapy, she stopped isavuconazole, noting that her

![Flow volume curves](image-url)

**Figure 1.** Flow volume curves. (A) Moderate airway obstruction while on voriconazole in December 2014 (forced expiratory volume [FEV], 1.61L, forced vital capacity [FVC] 2.38L, FEV/FVC 68%). (B) Mild airway obstruction after first course of isavuconazole in July 2015 (FEV$_1$, 2.12L, FVC 3.09L, FEV$_1$/FVC 69%). (C) Normal flow volume curve after the second course of isavuconazole in July 2016 (FEV$_1$, 2.43L, FVC 3.39L, FEV$_1$/FVC 72%).
Table 1. Selective Literature Review of Antifungal Therapies for the Treatment of ABPA in Patients With Asthma

| Reference | Study Design | Number of Patients | Compound(s) | Outcome Variables | Results | Adverse Effects |
|-----------|--------------|--------------------|-------------|-------------------|---------|-----------------|
| Jacobs et al | Current case report | N = 1 | Isavuconazole 200 mg 3x/day x 2 days, then 200 mg daily | Symptoms, PFTs, Biomarkers, Corticosteroids | o Symptomatic improvement  
 o Improvement in FEV, and FVC  
 o Reduction in total IgE  
 o Reduction in inhaled corticosteroids | Diarrhea |
| De Beule et al [11] | Prospective observational cohort study | N = 5 (of 137 patients with different forms of aspergillosis) | Itraconazole | Symptoms, Microbiology | o Symptomatic improvement in 4 of 5 patients  
 o Sterilization of sputum cultures in 3 of 4 patients with growth of Aspergillus species at baseline | Among the total cohort (N = 137), 18% had adverse effects. Dyspepsia, abdominal pain, nausea, diarrhea, dizziness were most common. |
| Denning et al [12] | Case series | N = 6 (N = 3 with asthma) | Itraconazole 200 mg twice daily | Symptoms, Biomarkers, Corticosteroids | o Symptomatic improvement in 3 of 3 patients  
 o Reduction in serum IgE by ≥50% in 2 of 3 patients  
 o Reduction in corticosteroid requirement in 1 of 3 patients | Decreased libido |
| Pacheco et al [13] | Case report | N = 1 | Itraconazole 200 mg/day | Biomarkers, PFTs, Corticosteroids | o Reduction in Aspergillus-specific serum IgG levels  
 o Improvement in FEV1, by 19% and in FVC by 28%  
 o Reduction in corticosteroid requirement | Not specified |
| Germaud and Tuchais [14] | Observational cohort study | N = 12 (N = 9 with asthma) | Itraconazole 200 mg/day | Symptoms, Biomarkers, Corticosteroids | o Overall response (clinical, laboratory, radiographic) in 11 patients  
 o Reduction in mean eosinophilia ~50%  
 o Reduction in mean serum IgE ~70%  
 o No change in Aspergillus-specific IgE  
 o Aspergillus precipitating antibodies became negative in 7 patients  
 o Reduction in corticosteroid use in 6 patients | None |
| Nikaido et al [15] | Case report | N = 1 | Itraconazole 100–150 mg/day | Biomarkers, PFTs, Radiology, Corticosteroids | o Reduction in IgE and eosinophilia  
 o Improvement in radiographic pulmonary infiltrates | None |
| Salez et al [16] | Prospective observational cohort study | N = 14 | Itraconazole 200 mg/day | ABPA exacerbations, PFTs, Biomarkers, Corticosteroids | o Mean number of exacerbations reduced from 2.4/year to 0.9/year (P < .01)  
 o Improvement in FEV1 and FEF25–75  
 o Reduction in eosinophilia by 50%  
 o Reduction in serum IgE by 50%  
 o Reduction in precipitating antibodies to Aspergillus fumigatus by 70%  
 o Decrease in corticosteroid use | None |
| Stevens et al [2] | Double-blind, placebo-controlled RCT | N = 55, followed by open label trial in 50 patients | Itraconazole 200 mg twice daily for 16 weeks, followed by 200 mg/day for 16 weeks | Symptoms, PFTs, Biomarkers, Radiology, Corticosteroids | o Overall response in 13 of 28 vs 5 of 27 patients receiving itraconazole versus placebo, respectively (P = .04)  
 o Improved exercise tolerance by ≥25%  
 o Improvement in ≥1 PFT  
 o Reduction in total IgE by ≥50%  
 o Reduction in corticosteroids by ≥50%  
 o No differences in improvement in radiographic pulmonary infiltrates | No difference between itraconazole (89%) versus placebo (85%). Presumed itraconazole-related: hair loss, dry mouth, hand tremors, increased perspiration, gastritis, diarrhea, constipation, forgetfulness, fatigue, and stomach cramps |
Table 1. Continued

| Reference                  | Study Design                        | Number of Patients | Compound(s)                     | Outcome Variables                      | Results                                                                 | Adverse Effects                                                                 |
|----------------------------|-------------------------------------|--------------------|---------------------------------|-----------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Wark et al [3]             | Double-blind, placebo-controlled RCT | N = 29             | Itraconazole 400 mg daily versus placebo | ABPA exacerbations PFTs Biomarkers     | o Median number of asthma exacerbations requiring prednisone: zero with itraconazole and 1.5 with placebo, \( P = .03 \) o No significant differences in FEV, or PEF o Significant reduction in median total serum IgE (\( P < .01 \)), sputum eosinophils (\( P < .01 \)), and specific IgE to A fumigatus in itraconazole-treated patients | Nausea (1 of 15 itraconazole-treated patients) |
| Coop et al [17]            | Case report                         | N = 1              | Itraconazole                   | Symptoms Biomarkers Radiology          | o Symptomatic improvement o Reduction in total IgE by >50% o Improvement in radiographic pulmonary infiltrates | Not specified |
| Ferrari et al [18]         | Case report                         | N = 1              | Itraconazole 200 mg twice daily | Symptoms Lung function                 | o Symptomatic improvement o Improvement in FEV, from 25% to 47% and in FVC from 42% to 72% | Renal failure and rhabdomyolysis |
| Rai et al [19]             | Retrospective cohort study          | N = 28 (including 13 patients treated with itraconazole and 15 controls) | Itraconazole 200 mg daily           | Symptoms Corticosteroids               | o Symptomatic improvement in 11 of 13 treated patients o Decreased requirement for rescue and maintenance corticosteroids in patients receiving itraconazole vs no antifungal therapy | None |
| Erwin and Fitzgerald [20]  | Case report                         | N = 1              | Itraconazole followed by voriconazole | Symptoms Biomarkers Corticosteroids   | o Itraconazole: no change in symptoms, transient decrease in corticosteroid exposure o Voriconazole: Symptomatic improvement, decrease in IgE by >50%, tapered off systemic corticosteroids | Not specified |
| Pasqualotto et al [21]     | Retrospective cohort study          | N = 11 (of 33 patients total; the other 22 patients had SAFS) | Itraconazole 100–450 mg daily       | PFTs Biomarkers Corticosteroids       | o Increased median FEV, \( (P = .08) \) o Reduction in serum IgE by 37% \( (P = .005) \) o Reduction in eosinophilia by 27% \( (P = .4) \) o Reduction in corticosteroid dose by 43% \( (P = .109) \) | Tendinitis Edema Diarrhea and rash Abnormal liver function tests Abdominal pain |
| Santos et al [22]          | Case report                         | N = 1              | Itraconazole 200 mg/day         | Symptoms PFTs Biomarkers Corticosteroids | o Symptomatic improvement o Improvement in FEV, and FVC o Reduction in serum IgE and eosinophilia o Improvement in radiographic pulmonary infiltrates o Reduction in corticosteroid dose | None |
| Tang and Zhang [23]        | Case report                         | N = 1              | Itraconazole 400 mg/day         | Symptoms ABPA exacerbations PFTs Biomarkers Radiology | o Symptomatic improvement and decrease in number of ABPA exacerbations o No changes in PFTs o Reduction in serum IgE o No improvement in radiographic pulmonary infiltrates | Not specified |
| Kirschner et al [24]       | Case report                         | N = 1              | Voriconazole 300 mg twice daily  | Symptoms Radiology                    | o Resolution of symptoms o Improvement in radiographic pulmonary infiltrates | Not specified |
| Chishimba et al [4]        | Retrospective observational cohort study | N = 20 with ABPA and 5 with SAFS (N = 17 with ABPA and asthma) | Voriconazole 300–600 mg/ day or Posaconazole 800 mg/ day | Symptoms PFTs Biomarkers Radiology Quality of life | o Clinical response at 6 months in 73% with voriconazole and 78% with posaconazole\( b \) o No significant changes in F EV, or FVC o Median total IgE decrease by 27% at 12 months o Improvement radiographic pulmonary infiltrates in 57% with voriconazole and 50% posaconazole o Quality of life improvement in 68% with voriconazole and 78% with posaconazole | Adverse effects occurred in 40% with voriconazole and 22% with posaconazole |
exercise tolerance was the best it had been in years. She generally tolerated isavuconazole well, with the exception of watery diarrhea that she attributed to the drug and that lingered for several weeks after stopping therapy. The serum AST and ALT remained within normal limits.

The patient continued to feel well throughout the fall 2015 and was maintained on budesonide-formoterol. On repeat PFTs, the FEV1 had improved to 2.42L, and the FEV1/FVC was 68%.

In January 2016, sputum production and wheezing increased, consistent with an ABPA exacerbation. The patient resumed isavuconazole in March 2016 with the same loading dose. Again she had marked symptomatic improvement, and she participated in 5 hiking trips during the spring and summertime. She stopped isavuconazole in May 2016. Pulmonary function tests were repeated in July 2016 and were within normal limits (FEV1 2.43L, FVC 3.39L, FEV1/FVC 72%) (Figure 1). As of January 2017, she continues to have minimal respiratory symptoms, and she has remained off systemic corticosteroids and weaned inhaled corticosteroids to 1 puff of budesonide/formoterol daily.

**DISCUSSION**

To our knowledge, this is the first report of the use of isavuconazole for treatment of ABPA. Based on this patient’s favorable clinical and physiological response to isavuconazole, we believe that isavuconazole is a viable treatment option for patients with ABPA.

Isavuconazonium sulfate is a prodrug of the active triazole moiety, isavuconazole. Similar to other triazoles, isavuconazole prevents fungal cell membrane synthesis via inhibition of lanosterol-14α-demethylase. Isavuconazole has in vitro activity against many yeasts and moulds including *Aspergillus* species, *Mucorales*, *Fusarium* species, and dematiaceous moulds. Isavuconazone reduces fungal burden and improves clinical outcomes in experimental models of disseminated aspergillosis and experimental fungal infections [6,7]. In humans, a randomized controlled clinical trial of patients with invasive aspergillosis (SECURE trial) demonstrated that isavuconazole had comparable survival rates to that of voriconazole and was safer and better tolerated [8]. This trial, combined with preclinical and clinical data, led to the approval of isavuconazole in the United States and in Europe in 2015.

**REVIEW OF THE LITERATURE**

We identified 3 randomized clinical trials and 16 observational studies (7 observational cohort studies, 1 case series, and 8 case reports) of itraconazole, voriconazole, posaconazole, and isavuconazole for the treatment of ABPA in patients with asthma (Table 1).

![Image](image_url)
for the first time in 7 years after ABPA diagnosis. This impact on PFTs after taking isavuconazole suggests that it was more effective than voriconazole, although we cannot exclude the possibility that prior courses of voriconazole or improved asthma symptom management also contributed to the difference. Of note, isavuconazole also had a corticosteroid-sparing effect for the patient thus reducing the risk for short-term and long-term adverse effects.

A potential explanation for the relatively greater response to treatment with isavuconazole versus voriconazole is that isavuconazole achieved higher drug exposure and a more rapid clearance of organism in comparison to voriconazole, for which therapeutic drug monitoring was not performed. An alternate explanation for subtherapeutic concentrations of voriconazole may be the phenomenon of autoinduction [9]. An advantage of isavuconazole is its predictable linear pharmacokinetics.

Treatment with isavuconazole is generally safe and well tolerated, a key distinguishing feature of the drug compared with other ABPA therapies. Unique adverse reactions among patients receiving voriconazole include transient vision changes, visual hallucinations, and photosensitivity [4]. Among patients on long-term therapy, periostitis and squamous cell carcinoma are concerns. Itraconazole is associated with gastrointestinal upset, congestive heart failure, rash, and increased liver enzymes. Posaconazole is associated with gastrointestinal upset depending on the formulation, and there are sparse data supporting its use for ABPA. Nebulized amphotericin B causes coughing and bronchospasm during inhalation [10].

CONCLUSIONS

In summary, we present the first report of a patient with underlying asthma and ABPA to be successfully treated with isavuconazole with minimal adverse effects. Based on this case report, we suggest consideration of an open-label or randomized trial of isavuconazole versus voriconazole for the treatment of ABPA in patients with underlying asthma.

Acknowledgments

T. J. W. is a Scholar of the Save Our Sick Children Foundation and a Scholar of the Sharp Family Foundation in Pediatric Emerging Infectious Diseases.

Financial support. This work was funded in part by the Save Our Sick Children Foundation (to T. J. W.).

Potential conflicts of interest. T. J. W. has received research grants for experimental and clinical antimicrobial pharmacotherapeutics from Astellas, Cubist, Novartis, Merck, Pfizer, Allergan, and Theravance. He also has served as consultant to Astellas, ContraFect, Cubist, Drais, iCo, Novartis, Pfizer, Methylegen, SigmaTau, and Trius. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43:850–73.
2. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756–62.
3. Wark PA, Hensley MJ, Salos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952–7.
4. Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012; 49:423–33.
5. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:1–60.
6. Warn PA, Sharp A, Mosquera J, et al. Comparative in vivo activity of BAL8557, the active component of the produg BAL8815, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 2006; 58:1198–207.
7. Kovanda LL, Petraitis R, Petraitis V, et al. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. J Antimicrob Chemother 2016; 71:1885–91.
8. Maertens JA, Raad II, Ghani AR, et al. Itraconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised, controlled, non-inferiority trial. Lancet 2015; 6736:1–10.
9. Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother 2009; 53:1712–4.
10. Ramm B, Aggarwal AN, Dhosia S, et al. A pilot RCT of nebulized amphotericin for maintenance of remission in patients with allergic bronchopulmonary aspergillosis. J Asthma 2015; 53:517–24.
11. De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergillosis with itraconazole, clinical results of an open international study (1982–1987). Mycoses 1998; 41:476–85.
12. Denning DW, Van Wye JE, Levison NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with voriconazole. Chest 1991; 100:813–9.
13. Pacheco A, Martin JA, Cuevas M. Serologic response to itraconazole in allergic bronchopulmonary aspergillosis. Chest 1993; 103:980–1.
14. Germaud P, Tuchais E. Allergic bronchopulmonary aspergillosis treated with itraconazole. Chest 1995; 107:883.
15. Nikaido Y, Nagata N, Yamamoto T, et al. A case of allergic bronchopulmonary aspergillosis successfully treated with voriconazole. J Invest Allergol Clin Immunol 2009; 19:404–8.
16. Saule F, Brichet A, Desurmont S, et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116:1665–8.
17. Coop C, England RW, Quinn JM. Aspergillosis masquerading as invasive pulmonary aspergillosis. Allergy Asthma Proc 2004; 25:263–6.
18. Ferrari M, Bodini I, Lo Cascio V. Rhadobdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis. Respiration 2004; 71:289–91.
19. Rai SP, Panda BN, Bhargava S. Treatment of allergic bronchopulmonary aspergillosis with fluconazole and itraconazole. Med J Armed Forces India 2004; 60:128–30.
20. Erwin GE, Fitzgerald JE. Case report: allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully treated with voriconazole. J Asthma 2007; 44:891–5.
21. Pasqualotto AC, Powell G, Niven R, Denning DW. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respir Med 2009; 103:1121–7.
22. Santos A, Loureiro G, Faria E, Chieira C. Itraconazole, an effective adjunctive treatment for allergic bronchopulmonary aspergillosis. J Investig Allergol Clin Immunol 2009; 19:404–8.
23. Tang R, Zhang HY. Aspirin induced asthma accompanied with allergic bronchopulmonary aspergillosis: a case report. Chin Med J (Engl) 2010; 123:2489–92.
24. Kirschner AN, Kuhlmann E, Kuźniar TJ, Eosinophilic pleural effusion complicating allergic bronchopulmonary aspergillosis. Respira tion 2011; 82:478–81.
25. Chishimba L, Langridge P, Powell G, et al. Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAPS) and allergic bronchopulmonary aspergillosis (ABPA). J Asthma 2015; 52:289–95.